BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Policy

  As Omicron Shatters Records, Pfizer Tweaks Vaccine

  Pfizer has reported that an Omicron-specific vaccine will be available in March, should it be necessary. For those and more COVID-19 news, continue reading.

  January 11, 2022

   · 

  6 min read

   · 

  Mark Terry
• 

  Drug Development

  Sarepta DMD Treatment Improves Motor Skills in Study Presented at JPM

  Sarepta Therapeutics shared positive topline results from its ongoing SRP-9001-102 study on the effectiveness of delandistrogene moxeparvovec in treating Duchenne muscular dystrophy.

  January 11, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Sana Doubles Efforts for CAR T Research with New Collaborations

  Seattle-based Sana Biotechnology went all-in on improving CAR T therapies against B cell cancers in two separate deals announced today.

  January 11, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Xenotransplant Advocates Rejoice as a Pig’s Heart Beats in Man’s Chest

  Gene editing has broken through to a new level as a Maryland man recovers from surgery in which a heart from a genetically modified pig may save his life.

  January 11, 2022

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Business

  $1 Billion Pfizer-Dren Bio Deal Highlights Another Day of Collaborations

  California-based Dren Bio and Pfizer have partnered on a deal valued at more than $1 billion to discover and develop therapeutic bispecific antibodies for select oncology targets.

  January 11, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Business

  Legendary Bayer is Reinventing its Story with Cell and Gene Therapy

  Bayer has transformed its pipeline by acquiring multiple cell and gene therapy companies, paving the way for life-saving and life-altering therapies for patients with different disease types.

  January 11, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Drug Development

  Oh, Where Vaccines Could Take Us

  2021 could very well have been “the year of the vaccine.” While this modality is certainly not new, the COVID-19 pandemic is sparking excitement about just what else they might be able to do.

  January 11, 2022

   · 

  6 min read

   · 

  Heather McKenzie
• 

  BioMidwest

  For mRNA Vaccines, Protection is Down to the T Follicular Helper Cells

  T follicular helper immune cells help antibody-producing cells create increasingly robust antibodies and also enhance the formation of certain types of immune memory.

  January 11, 2022

   · 

  4 min read

   · 

  Gail Dutton
• 

  Business

  Gameto Nets $20M on Path to Redefining Reproductive Longevity

  Gameto has created a three-part platform for ovarian therapeutics that will address menopause and assisted fertility.

  January 11, 2022

   · 

  2 min read

   · 

  Kaylei Whalen
• 

  Business

  Amgen and Arrakis Aim to Destroy Disease with Targeted RNA Degraders

  Amgen will partner with Arrakis Therapeutics for an innovative collaboration to research and develop RNA degrader therapeutics.

  January 11, 2022

   · 

  2 min read

   · 

  Alvin Clavines